AIM: To evaluate efficacy and safety of oral beclometasone dipropionate (BDP) when added to 5-ASA in the treatment of patients with active ulcerative colitis. METHODS: In a 4-week, placebo-controlled, double-blind study, patients with extensive or left-sided mild to moderate active ulcerative colitis were randomized to receive oral 5-ASA (3.2 g/day) plus BDP (5 mg/day) or placebo. Clinical, endoscopic and histologic features, and haematochemical parameters were recorded at baseline and at the end of the study.
Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study / Rizzello, F; Gionchetti, P; D'Arienzo, Agesilao; Manguso, F; Di Matteo, G; Annese, V; Valpiani, D; Casetti, T; Adamo, S; Prada, A; Castiglione, Gn; Varoli, G; Campieri, M.. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - ELETTRONICO. - 16:6(2002), pp. 1109-1116.
Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.
D'ARIENZO, AGESILAO;
2002
Abstract
AIM: To evaluate efficacy and safety of oral beclometasone dipropionate (BDP) when added to 5-ASA in the treatment of patients with active ulcerative colitis. METHODS: In a 4-week, placebo-controlled, double-blind study, patients with extensive or left-sided mild to moderate active ulcerative colitis were randomized to receive oral 5-ASA (3.2 g/day) plus BDP (5 mg/day) or placebo. Clinical, endoscopic and histologic features, and haematochemical parameters were recorded at baseline and at the end of the study.| File | Dimensione | Formato | |
|---|---|---|---|
|
aliment pharmacol ther 2002.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
149.38 kB
Formato
Adobe PDF
|
149.38 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
